.png){kind=icon}
返回
Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia
.png){kind=icon}
OA
AI
DOI：10.1016/j.xcrm.2024.101614.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor (LDLR) and mediates its internalization and degradation, resulting in an increase in LDL cholesterol levels. Recently, PCSK9 emerged as a therapeutic target for hypercholesterolemia and atherosclerosis. In this study, we develop a PCSK9 nanoparticle (NP) vaccine by covalently conjugating the catalytic domain (aa 153-aa 454, D374Y) of PCSK9 to self-assembled 24-mer ferritin NPs. We demonstrate that the PCSK9 NP vaccine effectively induces interfering antibodies against PCSK9 and reduces serum lipids levels in both a high-fat diet-induced hypercholesterolemia model and an adeno-associated virus-hPCSK9D374Y-induced D374Y-induced hypercholesterolemia model. Additionally, the vaccine significantly reduces plaque lesion areas in the aorta and macrophages infiltration in an atherosclerosis mouse model. Furthermore, we discover that the vaccine's efficacy relied on T follicular help cells and LDLR. Overall, these findings suggest that the PCSK9 NP vaccine holds promise as an effective treatment for hypercholesterolemia and atherosclerosis.
Keyword:
LDL-CHOLESTEROL
T-CELLS
PCSK9
DIFFERENTIATION
IMMUNIZATION
MUTATIONS
INDUCTION
EFFICACY
VECTOR
MICE
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
10.6
论文数:
2.3K
被引数:
1.0W
机构
引用论文
分享收藏分享收藏CD4+ Cytotoxic T cells - Phenotype, Function and Transcriptional Networks Controlling Their Differentiation PathwaysCD4细胞毒性T细胞-表型，功能和控制其分化途径的转录网络.png)
IMMUNOLOGY LETTERS
IMMUNOLOGY LETTERSIF2.8
PREAI
分享收藏Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus PanelEUROPEAN HEART JOURNALOAAI
EUROPEAN HEART JOURNALIF35.6
OAAI分享收藏
查看更多内容